Sumitomo Pharma Co., Ltd.
DNPUF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.02 | -0.31 | -0.01 |
| FCF Yield | 2.52% | -0.00% | 3.04% | -0.43% |
| EV / EBITDA | 10.50 | 25.28 | 100.98 | 19.92 |
| Quality | ||||
| ROIC | 4.32% | 3.47% | -0.12% | 3.34% |
| Gross Margin | 61.73% | 59.16% | 62.45% | 63.14% |
| Cash Conversion Ratio | 0.21 | -0.00 | 4.56 | 0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.63% | -4.07% | -10.46% | -14.11% |
| Free Cash Flow Growth | 1,103.91% | -100.13% | 872.27% | -104.02% |
| Safety | ||||
| Net Debt / EBITDA | 2.60 | 11.01 | 50.38 | 10.52 |
| Interest Coverage | 0.00 | 2.41 | 0.08 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.55 | 0.49 | 0.42 | 0.39 |
| Cash Conversion Cycle | 176.52 | 172.40 | 190.07 | 201.79 |